GRANULES INDIA LTD.-$ - 532482 - Closure of Trading Window
Closure of Trading Window27-06-2024
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analyst/Investor Meet05-06-2024
Granules India Promoter Pares Stake For Rs 303 Crore
The promoter sold 75 lakh shares, representing 3.09% stake, for Rs 405.08 per share, according to block deal data on the NSE.22-05-2024
GRANULES INDIA LTD.-$ - 532482 - Transcript Of The Earnings Conference Call For Q4 And Financial Year Ended On March 31, 2024.
Transcript of the Earnings Conference Call for Q4 and Financial Year ended on March 31, 202421-05-2024
Granules India Q4 Results Review - Higher Finished Dosage Sales Drives Earnings: Dolat Capital
Lower demand impacts active pharma ingredient and pharmaceutical formulation intermediate sales16-05-2024
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of the Earnings Call for Q4 and FY2415-05-2024
Q4FY24 Quarterly Result Announced for Granules India Ltd.
Pharmaceuticals company Granules India announced Q4FY24 results: Revenue from Operations of Q4FY24 stood at Rs 11,758 million, a decline of 2% YoY. Formulations including GPI manufactured products grew by 41%. Revenue share from the North America increased to 70% in Q4FY24 as compared to 58% in Q4FY23. Decline in Para API sales volume and price erosion. Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished dosages contribute 14%, 13%, and 73% of revenue from operations respectively for Q4FY24. ROCE is at 16.5% as compared to 21.2% YoY. Net debt stood at Rs 8,421 million and Net debt to EBITDA at 0.98x. Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “We had a strong uptick in gross margin for the Q4 and for the full year, with continued growth in formulations share coming from US and Europe as part of our global expansion strategy and a higher contribution from new products. While the fiscal year numbers were below expectations due to cyber incident and low paracetamol demand, we are very excited about the way our strategies for the future are playing out and look forward to the upcoming years.” Result PDF15-05-2024
GRANULES INDIA LTD.-$ - 532482 - Book Closure Date For The Purpose Of Annual General Meeting
Book Closure Date for the purpose of the Annual General Meeting15-05-2024
GRANULES INDIA LTD.-$ - 532482 - Record Date For Payment Of Final Dividend For FY2023-24
Record Date for payment of Final Dividend for FY2023-2415-05-2024